Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

Shares of Trevena stock opened at $1.69 on Thursday. Trevena has a 1 year low of $1.13 and a 1 year high of $17.50. The company’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $3.02.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million for the quarter. Equities analysts forecast that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.